Flash-Player installieren

» Flash-Player installieren
» Watch video in bigger size

ScheBo® · Biotech AG
Netanyastrasse 3
35394 Giessen

Phone +49 (0)641 / 4996-0
Fax +49 (0)641 / 4996-77

ScheBo® Pancreatic Elastase 1™

Tests for the quantification of human pancreatic elastase 1

Two ELISA test kits (based on monoclonal antibodies) are available for the determination of pancreatic elastase 1.
The stool test quantifies E1 in stool, allowing the diagnosis or exclusion of pancreatic exocrine insufficiency, which can be caused by chronic pancreatitis, cystic fibrosis, pancreatic tumor, cholelithiasis or diabetes mellitus for example.
The serum test quantifies E1 in serum, allowing the diagnosis or exclusion of an acute pancreatitis or an inflammatory episode of chronic pancreatitis or ERCP- or gallstone-induced pancreatitis.

Stool Test

Human pancreatic elastase 1 (E1) remains undegraded during intestinal transit. Therefore its concentration in faeces reflects pancreatic exocrine function. The diagnostic efficiency of pancreatic elastase 1 determination in stool has been evaluated in several clinical studies. Stein et al. (1993 & 1996, 1997) and Löser et al. (1995 & 1996) compared the E1 determination with invasive intubation tests, the secretin-pancreozymin test and the secretin-caerulein test, respectively. Both authors report a sensitivity and specificity greater than 90% for the diagnosis of exocrine pancreatic insufficiency. In contrast to the fecal chymotrypsin assay, even a moderate pancreatic insufficiency can be detected by E1 determination (Löser et al., 1995 & 1996, Gullo et al., 1999).

Serum Test

Human pancreatic elastase 1 is synthesized from the acinar cells of the pancreas. During an inflammatory episode of the pancreas, E1 is released into the blood circulation. Thus the quantification of pancreatic elastase 1 in the serum allows diagnosis or exclusion of acute pancreatitis.

Multicenter Study: Newest data on the M2-PK test published in journal "Gut and Liver"
Korean Scientists have published the very newest data on the M2-PK test in the renowned specialist journal ‚Gut and Liver‘.
New ScheBo® · Pancreas Elastase 1 Quick™ Canine test
The stool test for the fast and reliable diagnosis/ exclusion of Exocrine Pancreatic Insufficiency in canine is
… now also available as a rapid test
New ScheBo® · Pancreas Elastase 1 Quick™ test
Faecal Pancreatic Elastase 1
The Gold Standard for Non-Invasive Exocrine Pancreatic Function Testing
… now also available as a rapid test
2in1 Colorectal Cancer Screening Test
New innovative combined rapid test to simultaneously detect the enzyme biomarker M2-PK and human haemoglobin for improved colorectal cancer screening.
Meta-analysis published of faecal M2-PK in colorectal cancer screening
Authors conclude that "We recommend faecal M2-PK as a routine test for CRC screening".
Biomarker ′M2-PK′ Identified as Key Enzyme in Cancer Diagnosis and Therapy
Ground Breaking Findings on Understanding Cancer Published in ′Science′
Video: Focus 2010 lecture on M2-PK
The high sensitivity (c.80%) and high specificity (>90%) of the M2-PK stool test for colorectal cancer screening and detection, plus benefits for patients, laboratories and doctors, was presented at Focus 2010
Tumour M2-PK as a stool marker for colorectal cancer
Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients.
Coeliac disease and pancreatic exocrine insufficiency
The data have shown that pancreatic insufficiency, demonstrated by low faecal pancreatic elastase-1 levels, is common in adult coeliac disease patients.